Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Surgical outcomes from the Phase III CheckMate 816 trialПодробнее

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023Подробнее

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IOПодробнее

Perioperative therapies in NSCLCПодробнее

8 in 8 Series: Neoadjuvant Biomarker Trials in Lung CancerПодробнее

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...Подробнее

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

Event-free survival results from CheckMate 816Подробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

Neoadjuvant nivolumab + chemo continues to provide long-term clinical benefit for NSCLC patientsПодробнее

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022Подробнее

Dr. Boman Dhabar -(NIVO)+platinum-doublet chemo vs chemo alone as neoadjuvant treatment for patientsПодробнее

Future directions for neoadjuvant immunotherapy in lung cancerПодробнее

The rationale and trial design of the NADIM II trialПодробнее

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022Подробнее

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023Подробнее

CheckMate 816: what does the data tell us?Подробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Подробнее